NU-7107

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406410

CAS#: 503465-21-2

Description: NU-7107 is a potent DNA-PK inhibitor with potential anticancer activity.


Price and Availability

Size
Price

Size
Price

Size
Price

NU-7107 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 406410
Name: NU-7107
CAS#: 503465-21-2
Chemical Formula: C18H19N3O2
Exact Mass: 309.14773
Molecular Weight: 309.36236
Elemental Analysis: C, 69.88; H, 6.19; N, 13.58; O, 10.34


Synonym: NU7107; NU 7107; NU-7107.

IUPAC/Chemical Name: 2-((2R,6S)-2,6-dimethylmorpholino)-4H-pyrimido[2,1-a]isoquinolin-4-one

InChi Key: WEXIWJYAPCUIPH-BETUJISGSA-N

InChi Code: InChI=1S/C18H19N3O2/c1-12-10-20(11-13(2)23-12)16-9-17(22)21-8-7-14-5-3-4-6-15(14)18(21)19-16/h3-9,12-13H,10-11H2,1-2H3/t12-,13+

SMILES Code: O=C1C=C(N2C[C@@H](C)O[C@@H](C)C2)N=C3N1C=CC4=C3C=CC=C4


Technical Data

Appearance:
solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

  
 
 
 


References

1. Nutley BP, Smith NF, Hayes A, Kelland LR, Brunton L, Golding BT, Smith GC, Martin NM, Workman P, Raynaud FI. Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026. Br. J. Cancer (2005)